Can Grail's Galleri Cancer Test Still Win Approval?

Grail, a mid-cap healthcare company, is navigating a critical period for its multi-cancer early detection (MCED) test, Galleri. The Galleri test is engineered to identify more than 50 types of cancer at their initial stages, a development that could significantly improve patient prognoses and reduce the financial burden associated with late-stage cancer treatments.

Despite promising potential, Grail faced a setback in February 2026 when top-line results from its NHS trial in England revealed the test did not meet its primary endpoint. This endpoint aimed to demonstrate a statistically significant reduction in Stage III-IV cancers among the tested group compared to a control. The news led to a substantial sell-off of Grail's stock.

However, the company is actively working to secure FDA approval and coverage from medical insurers. Management is preparing to present 12-month follow-up data from the NHS trial, anticipating it will strengthen their case. Grail's Chief Financial Officer, Aaron Freidin, expressed optimism that this additional data will help demonstrate Galleri's efficacy in detecting cancers that may not yet be clinically apparent.

The company continues its dialogue with the FDA, aiming to provide further evidence of Galleri's suitability for widespread medical use. The path forward involves convincing regulators and insurers of the test's benefits, even after the trial's primary endpoint was missed.